Scinai Immunotherapeutics Ltd. announced the completion of its acquisition of Recipharm Israel Ltd., marking a strategic expansion into Active Pharmaceutical Ingredient (API) development and manufacturing. The development, announced on April 10, 2026, also includes a commercial collaboration with Recipharm to strengthen end-to-end drug development capabilities.
Expanding API Development and Manufacturing
The acquired facility is a cGMP-certified site specializing in early-stage chemistry development and small-scale API manufacturing. This enables Scinai to support pharmaceutical companies in the initial phases of drug development, including clinical trial material production.
By integrating API development capabilities, the company is expanding its role from a research-focused organization to a more comprehensive contract development and manufacturing (CDMO) service provider.
Strengthening End-to-End CDMO Capabilities
As part of the agreement, Scinai has entered into a strategic collaboration with Recipharm. This partnership connects early-stage API development with late-stage and commercial-scale manufacturing capabilities.
The collaboration is expected to create a seamless pathway for pharmaceutical clients, covering:
- Early-stage API development and synthesis
- Clinical-scale manufacturing
- Late-stage development and commercialization support
This integrated model enhances efficiency and reduces time-to-market for new drug candidates.
Enhancing Global Pharmaceutical Development Services
The acquisition allows Scinai to broaden its service offerings and attract global pharmaceutical and biotech clients seeking flexible and scalable development solutions. The facility’s expertise in process chemistry and API synthesis strengthens its ability to deliver high-quality materials for clinical research.
Additionally, the move aligns with increasing demand for specialized CDMO services that combine innovation, regulatory compliance, and manufacturing scalability.
Strategic Shift Toward Integrated Pharma Solutions
The announcement highlights a broader industry trend where companies are expanding across the pharmaceutical value chain to capture higher value and improve operational control. By adding API capabilities, Scinai is positioning itself as a more integrated partner for drug development programs.
Outlook
The development announced on April 10, 2026, underscores the growing importance of early-stage API development and integrated CDMO models in the pharmaceutical industry. As demand for flexible and efficient development pathways increases, such strategic acquisitions are expected to play a key role in shaping the future of API manufacturing and drug development.
With this move, Scinai Immunotherapeutics Ltd. is strengthening its presence in the API and CDMO space while enhancing its ability to support pharmaceutical innovation from early development through commercialization.
